このページの翻訳は実験的なもので、現在開発中です。お待ちしております!
Merus 将来の成長
Future 基準チェック /26
Merus利益と収益がそれぞれ年間22.5%と49.6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-29.1% 27.8%なると予測されています。
主要情報
22.1%
収益成長率
27.6%
EPS成長率
Biotechs 収益成長 | 24.6% |
収益成長率 | 49.6% |
将来の株主資本利益率 | -29.1% |
アナリストカバレッジ | Good |
最終更新日 | 16 Jun 2024 |
今後の成長に関する最新情報
Recent updates
Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts
Jun 01Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
May 24Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
May 12Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans
May 10Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement
Mar 01Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 01Merus Stock: Rally Seems Overdone
Jan 23Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?
Jan 14Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)
Dec 18We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully
Sep 19Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price
Jun 20Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?
May 24Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate
Feb 08Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M
Aug 08Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies
Aug 02Merus: Precision Oncology Pioneer Continues To Execute In The Clinic
Jun 30Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)
May 14Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business
Apr 25New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)
Mar 03We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn
Nov 25News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts
Aug 08Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)
Jul 28We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
Jul 02Merus posts positive efficacy data from early-stage zenocutuzumab cancer study
Jun 04業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2026 | 108 | -215 | -154 | -200 | 11 |
12/31/2025 | 54 | -223 | -188 | -180 | 13 |
12/31/2024 | 41 | -176 | -171 | -156 | 13 |
3/31/2024 | 38 | -150 | -150 | -150 | N/A |
12/31/2023 | 44 | -155 | -146 | -142 | N/A |
9/30/2023 | 46 | -177 | -142 | -136 | N/A |
6/30/2023 | 41 | -178 | -159 | -150 | N/A |
3/31/2023 | 43 | -152 | -151 | -140 | N/A |
12/31/2022 | 42 | -131 | -158 | -150 | N/A |
9/30/2022 | 46 | -64 | -157 | -151 | N/A |
6/30/2022 | 53 | -54 | -137 | -133 | N/A |
3/31/2022 | 52 | -76 | -126 | -125 | N/A |
12/31/2021 | 49 | -67 | -60 | -60 | N/A |
9/30/2021 | 43 | -80 | -53 | -52 | N/A |
6/30/2021 | 38 | -89 | -42 | -41 | N/A |
3/31/2021 | 32 | -79 | -37 | -35 | N/A |
12/31/2020 | 30 | -86 | -81 | -80 | N/A |
9/30/2020 | 29 | -83 | -76 | -75 | N/A |
6/30/2020 | 28 | -69 | -80 | -78 | N/A |
3/31/2020 | 29 | -65 | -77 | -75 | N/A |
12/31/2019 | 31 | -55 | -66 | -63 | N/A |
9/30/2019 | 37 | -32 | -61 | -56 | N/A |
6/30/2019 | 35 | -34 | -63 | -58 | N/A |
3/31/2019 | 36 | -26 | -50 | -45 | N/A |
12/31/2018 | 38 | -28 | -50 | -46 | N/A |
9/30/2018 | 34 | -41 | -48 | -46 | N/A |
6/30/2018 | 33 | -45 | -44 | -43 | N/A |
3/31/2018 | 34 | -66 | -55 | -54 | N/A |
12/31/2017 | 26 | -78 | N/A | -45 | N/A |
9/30/2017 | 18 | -100 | N/A | -44 | N/A |
6/30/2017 | 12 | -87 | N/A | -33 | N/A |
3/31/2017 | 6 | -66 | N/A | -27 | N/A |
12/31/2016 | 3 | -50 | N/A | -27 | N/A |
9/30/2016 | 4 | -25 | N/A | -27 | N/A |
6/30/2016 | 3 | -26 | N/A | -30 | N/A |
3/31/2016 | 3 | -27 | N/A | -29 | N/A |
12/31/2015 | 2 | -25 | N/A | -25 | N/A |
9/30/2015 | 2 | -25 | N/A | -23 | N/A |
6/30/2015 | 2 | -23 | N/A | -19 | N/A |
3/31/2015 | 1 | -20 | N/A | -17 | N/A |
12/31/2014 | 2 | -21 | N/A | -18 | N/A |
12/31/2013 | 1 | -14 | N/A | -10 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: MRUS今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: MRUS今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: MRUS今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: MRUSの収益 ( 49.6% ) US市場 ( 8.5% ) よりも速いペースで成長すると予測されています。
高い収益成長: MRUSの収益 ( 49.6% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: MRUS 3 年以内に赤字になると予測されています。